S165: Recent trends in biocatalysis for the synthesis of pharmaceutical intermediates at Pfizer

Biocatalysis is an integral part of process development for pharmaceutical intermediates and active pharmaceutical ingredients (API) at Pfizer. Several commercial processes for the synthesis of various API’s are being run using enzyme catalysis as the key step. In recent years, we have expanded the use of enzyme catalysis beyond the traditional use of more evolved enzyme classes such as hydrolases and keto reductases. Recent examples from Pfizer portfolio using diverse classes of enzymes will be presented.